Normal view
-
cs.AI, q-bio.NC updates on arXiv.org
-
Claw-Anything: Benchmarking Always-On Personal Assistants with Broader Access to User's Digital World
arXiv:2605.26086v1 Announce Type: new Abstract: Large language model agents are increasingly envisioned as always-on personal assistants with access to anything relevant in the user's digital world. Yet current systems operate over only narrow slices of that world, limiting context-sensitive reasoning and effective assistance. Existing benchmarks similarly provide only partial user state and therefore fail to capture performance in such a broad, always-on setting. To address this gap, we introd
-
cs.AI, q-bio.NC updates on arXiv.org
-
MobileGym: A Verifiable and Highly Parallel Simulation Platform for Mobile GUI Agent Research
arXiv:2605.26114v1 Announce Type: new Abstract: We present MobileGym, a browser-hosted, lightweight, fully controllable environment for everyday mobile use, targeting interaction fidelity without replicating proprietary backends. It enables two capabilities previously out of reach for everyday apps: verifiable outcome signals through deterministic state-based judging over structured JSON state, and scalable online RL through low-cost parallel rollouts. The full environment state is captured, co
MobileGym: A Verifiable and Highly Parallel Simulation Platform for Mobile GUI Agent Research
-
cs.AI, q-bio.NC updates on arXiv.org
-
Agent World Model: Infinity Synthetic Environments for Agentic Reinforcement Learning
arXiv:2602.10090v3 Announce Type: replace Abstract: Recent advances in large language model (LLM) have empowered autonomous agents to perform multi-turn interactions with tools and environments. However, scaling such agent training is limited by the lack of diverse and reliable environments. In this paper, we propose Agent World Model (AWM), a fully synthetic environment generation pipeline. Using this pipeline, we scale to 1,000 environments covering everyday scenarios, in which agents can int
Agent World Model: Infinity Synthetic Environments for Agentic Reinforcement Learning
-
cs.AI, q-bio.NC updates on arXiv.org
-
HiTeC: Hierarchical Contrastive Learning on Text-Attributed Hypergraph with Semantic-Aware Augmentation
arXiv:2508.03104v3 Announce Type: replace-cross Abstract: Contrastive learning (CL) has become a dominant paradigm for self-supervised hypergraph learning, enabling effective training without costly labels. However, node entities in real-world hypergraphs are often associated with rich textual information, which has been largely ignored in prior works. Directly applying existing CL-based methods to such text-attributed hypergraphs (TAHGs) leads to three key limitations: (1) The common use of gr
HiTeC: Hierarchical Contrastive Learning on Text-Attributed Hypergraph with Semantic-Aware Augmentation
-
(Multiomics OR Omics) AND (Lung OR gastric OR Hepatocellular)
-
Multi-omics analysis identified serum B4GALT1 as a prognostic factor for small cell lung cancer
J Thorac Dis. 2026 Apr 30;18(4):353. doi: 10.21037/jtd-2025-1-2610. Epub 2026 Mar 20.ABSTRACTBACKGROUND: Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor characterized by rapid progression, early metastasis, and high mortality, with limited effective long-term treatment options. B4GALT1, a β-1,4-galactosyltransferase, has been implicated in the malignant progression of various cancers, but its specific role and underlying mechanisms in SCLC remain largely unexplored. We conduc
Multi-omics analysis identified serum B4GALT1 as a prognostic factor for small cell lung cancer
J Thorac Dis. 2026 Apr 30;18(4):353. doi: 10.21037/jtd-2025-1-2610. Epub 2026 Mar 20.
ABSTRACT
BACKGROUND: Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor characterized by rapid progression, early metastasis, and high mortality, with limited effective long-term treatment options. B4GALT1, a β-1,4-galactosyltransferase, has been implicated in the malignant progression of various cancers, but its specific role and underlying mechanisms in SCLC remain largely unexplored. We conducted a multi-omics analysis and clinical sample study to explore the function of B4GALT1 in SCLC.
METHODS: This study comprehensively investigated the expression pattern, functional significance, and clinical relevance of B4GALT1 in SCLC. We conducted multi-omics analyses, including single-cell data processing, InferCNV analysis, and immune infiltration analysis, to explore the association between B4GALT1 and the immune microenvironment of SCLC and patient survival. To determine B4GALT1 as a potential circulating biomarker, quantitative data-independent acquisition (DIA) proteomics analysis was performed on serum samples from SCLC patients and healthy controls. Enzyme-linked immunosorbent assay (ELISA) was used to further verify the differential expression of serum B4GALT1 in a larger cohort of SCLC patients, to evaluate its diagnostic, prognostic, and treatment response predictive value.
RESULTS: Multi-omics analysis revealed that B4GALT1 expression was significantly associated with patient survival. The expression of B4GALT1 positively correlated with macrophage infiltration in the tumor and negatively correlated with CD4+ T cells in the tumor. There was a negative correlation in inactivated naïve B cells, eosinophils, and CD4 naïve T cells, while it showed a positive correlation in dendritic cells, M0/M1/M2 macrophages, natural killer (NK) cells, CD8 T cells, follicular helper T cells, and regulatory T cells. ELISA results showed that serum protein B4GALT1 expression was higher in patients with SCLC than in healthy controls. Elevated serum B4GALT1 protein levels correlated with poor treatment outcomes in patients with SCLC undergoing chemoradiotherapy.
CONCLUSIONS: Our findings establish B4GALT1 as a critical prognostic, diagnostic, and predictive biomarker in SCLC, with its expression closely linked to the tumor immune microenvironment and treatment response. Targeting B4GALT1 or its related pathways may represent a novel therapeutic strategy, and serum B4GALT1 holds promise as a liquid biopsy marker for SCLC patient stratification, monitoring, and guiding treatment decisions.
PMID:42182735 | PMC:PMC13190155 | DOI:10.21037/jtd-2025-1-2610
-
Omics In Lung
-
Multi-omics analysis identified serum B4GALT1 as a prognostic factor for small cell lung cancer
J Thorac Dis. 2026 Apr 30;18(4):353. doi: 10.21037/jtd-2025-1-2610. Epub 2026 Mar 20.ABSTRACTBACKGROUND: Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor characterized by rapid progression, early metastasis, and high mortality, with limited effective long-term treatment options. B4GALT1, a β-1,4-galactosyltransferase, has been implicated in the malignant progression of various cancers, but its specific role and underlying mechanisms in SCLC remain largely unexplored. We conduc
Multi-omics analysis identified serum B4GALT1 as a prognostic factor for small cell lung cancer
J Thorac Dis. 2026 Apr 30;18(4):353. doi: 10.21037/jtd-2025-1-2610. Epub 2026 Mar 20.
ABSTRACT
BACKGROUND: Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor characterized by rapid progression, early metastasis, and high mortality, with limited effective long-term treatment options. B4GALT1, a β-1,4-galactosyltransferase, has been implicated in the malignant progression of various cancers, but its specific role and underlying mechanisms in SCLC remain largely unexplored. We conducted a multi-omics analysis and clinical sample study to explore the function of B4GALT1 in SCLC.
METHODS: This study comprehensively investigated the expression pattern, functional significance, and clinical relevance of B4GALT1 in SCLC. We conducted multi-omics analyses, including single-cell data processing, InferCNV analysis, and immune infiltration analysis, to explore the association between B4GALT1 and the immune microenvironment of SCLC and patient survival. To determine B4GALT1 as a potential circulating biomarker, quantitative data-independent acquisition (DIA) proteomics analysis was performed on serum samples from SCLC patients and healthy controls. Enzyme-linked immunosorbent assay (ELISA) was used to further verify the differential expression of serum B4GALT1 in a larger cohort of SCLC patients, to evaluate its diagnostic, prognostic, and treatment response predictive value.
RESULTS: Multi-omics analysis revealed that B4GALT1 expression was significantly associated with patient survival. The expression of B4GALT1 positively correlated with macrophage infiltration in the tumor and negatively correlated with CD4+ T cells in the tumor. There was a negative correlation in inactivated naïve B cells, eosinophils, and CD4 naïve T cells, while it showed a positive correlation in dendritic cells, M0/M1/M2 macrophages, natural killer (NK) cells, CD8 T cells, follicular helper T cells, and regulatory T cells. ELISA results showed that serum protein B4GALT1 expression was higher in patients with SCLC than in healthy controls. Elevated serum B4GALT1 protein levels correlated with poor treatment outcomes in patients with SCLC undergoing chemoradiotherapy.
CONCLUSIONS: Our findings establish B4GALT1 as a critical prognostic, diagnostic, and predictive biomarker in SCLC, with its expression closely linked to the tumor immune microenvironment and treatment response. Targeting B4GALT1 or its related pathways may represent a novel therapeutic strategy, and serum B4GALT1 holds promise as a liquid biopsy marker for SCLC patient stratification, monitoring, and guiding treatment decisions.
PMID:42182735 | PMC:PMC13190155 | DOI:10.21037/jtd-2025-1-2610